跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 8,680 条关于
“CLN-081/TAS6417”
全部
8,680
临床试验
5,452
药物
2,534
机构
25
资讯
669
4年前
Cullinan Oncology and Taiho Pharmaceutical Forge $275M Strategic Collaboration for EGFR Inhibitor CLN-081/TAS6417
去年
Zipalertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion Mutations
上个月
Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 REZILIENT3 Trial for First-Line EGFR Exon 20 Insertion NSCLC
前天
Zipalertinib Plus Chemotherapy Cuts Progression Risk 50% in First-Line EGFR Exon 20 Insertion NSCLC
2年前
Cullinan Therapeutics Advances CLN-978 for SLE Treatment with Phase 1 Trial Approval
去年
AAVantgarde Bio Doses First Patient in Phase 1/2 Trial of AAVB-081 for Usher Syndrome Type 1B
10个月前
Cullinan Therapeutics Reports Promising 30% Response Rate for CLN-049 T Cell Engager in Relapsed AML Patients
去年
OncoC4's AI-081, a PD-1/VEGF Bispecific Antibody, Receives FDA IND Clearance for Advanced Solid Tumors
去年
OncoC4 Advances PD-1/VEGF Bispecific Antibody AI-081 to Phase 2 Trial Following Promising Early Efficacy Data
4个月前
Cullinan Therapeutics Receives FDA Orphan Drug Designation for Novel FLT3xCD3 T Cell Engager CLN-049 in Relapsed/Refractory AML
第 1 页,共 67 页
上一页
下一页